Repligen (NASDAQ:RGEN) Shares Down 6.4% – Should You Sell?

Repligen Corporation (NASDAQ:RGEN) shares were down 6.4% during trading on Thursday. The stock traded as low as $180.05 and last traded at $179.9820. 656,256 shares traded hands during trading, a decline of 36% from the average daily volume of 1,020,536 shares. The stock had previously closed at $192.23.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Wells Fargo & Company boosted their target price on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. raised their price target on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Citigroup upgraded Repligen to a “buy” rating in a research note on Tuesday, July 7th. UBS Group restated a “buy” rating on shares of Repligen in a report on Tuesday. Finally, Evercore reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $168.57.

Repligen Trading Up 2.5%

The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The stock has a 50-day simple moving average of $170.38 and a 200 day simple moving average of $141.32. The company has a market cap of $10.26 billion, a price-to-earnings ratio of 248.90, a PEG ratio of 3.23 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. The firm had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities research analysts predict that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Institutional Trading of Repligen

Several large investors have recently made changes to their positions in RGEN. ABS Investment Management LLC acquired a new stake in Repligen during the 2nd quarter worth about $191,016,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Repligen in the 2nd quarter valued at about $52,000. Trust Co. of Vermont purchased a new stake in shares of Repligen in the second quarter worth about $71,000. Harbor Investment Advisory LLC boosted its stake in shares of Repligen by 198.9% in the second quarter. Harbor Investment Advisory LLC now owns 523 shares of the biotechnology company’s stock worth $71,000 after buying an additional 348 shares during the last quarter. Finally, Allworth Financial LP acquired a new stake in Repligen during the second quarter worth about $71,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.